First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
Saved in:
| Title: | First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. |
|---|---|
| Authors: | Kim SB; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. sbkim3@amc.seoul.kr., Meric-Bernstam F; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kalyan A; Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Babich A; Bayer AG, Berlin, Germany., Liu R; Bayer Healthcare, Whippany, NJ, USA., Tanigawa T; Bayer Yakuhin, Ltd., Osaka, Japan., Sommer A; Bayer AG, Berlin, Germany., Osada M; Bayer AG, Berlin, Germany., Reetz F; Bayer AG, Basel, Switzerland., Laurent D; Bayer AG, Berlin, Germany., Wittemer-Rump S; Bayer AG, Berlin, Germany., Berlin J; Vanderbilt University Medical Center, Nashville, TN, USA. |
| Source: | Targeted oncology [Target Oncol] 2019 Oct; Vol. 14 (5), pp. 591-601. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 31502117 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Kim+SB%22">Kim SB</searchLink>; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. sbkim3@amc.seoul.kr.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kalyan+A%22">Kalyan A</searchLink>; Northwestern University Feinberg School of Medicine, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Babich+A%22">Babich A</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Liu+R%22">Liu R</searchLink>; Bayer Healthcare, Whippany, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Tanigawa+T%22">Tanigawa T</searchLink>; Bayer Yakuhin, Ltd., Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Sommer+A%22">Sommer A</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Osada+M%22">Osada M</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Reetz+F%22">Reetz F</searchLink>; Bayer AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Laurent+D%22">Laurent D</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Wittemer-Rump+S%22">Wittemer-Rump S</searchLink>; Bayer AG, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Berlin+J%22">Berlin J</searchLink>; Vanderbilt University Medical Center, Nashville, TN, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101270595%22">Targeted oncology</searchLink> [Target Oncol] 2019 Oct; Vol. 14 (5), pp. 591-601. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer-Verlag+France%22">Springer-Verlag France </searchLink><i>Country of Publication: </i>France <i>NLM ID: </i>101270595 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1776-260X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217762596%22">17762596 </searchLink><i>NLM ISO Abbreviation: </i>Target Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31502117 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s11523-019-00670-4 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 591 Titles: – TitleFull: First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Kim SB – PersonEntity: Name: NameFull: Meric-Bernstam F – PersonEntity: Name: NameFull: Kalyan A – PersonEntity: Name: NameFull: Babich A – PersonEntity: Name: NameFull: Liu R – PersonEntity: Name: NameFull: Tanigawa T – PersonEntity: Name: NameFull: Sommer A – PersonEntity: Name: NameFull: Osada M – PersonEntity: Name: NameFull: Reetz F – PersonEntity: Name: NameFull: Laurent D – PersonEntity: Name: NameFull: Wittemer-Rump S – PersonEntity: Name: NameFull: Berlin J IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2019 Oct Type: published Y: 2019 Identifiers: – Type: issn-electronic Value: 1776-260X Numbering: – Type: volume Value: 14 – Type: issue Value: 5 Titles: – TitleFull: Targeted oncology Type: main |
| ResultId | 1 |
